From Financial Modeling Prep: 2024-12-17 11:21:00

Quest Diagnostics (NYSE:DGX) saw a 1% rise in shares after Morgan Stanley upgraded the company to Overweight with a price target of $172. The upgrade reflects confidence in Quest’s growth prospects and ability to sustain momentum into 2025.

Morgan Stanley, previously cautious on Quest’s recovery, now sees the company well-positioned to benefit from strong healthcare utilization trends and election-related risks. Quest has reaffirmed its long-term growth targets, anticipating 3% organic revenue growth annually through 2026.

Quest Diagnostics expects high-single-digit earnings growth, margin expansion, and M&A contributions to drive mid-single-digit revenue growth and sustained earnings improvement. With favorable trends and a positive outlook, the company is positioned for continued growth and shareholder value creation.



Read more at Financial Modeling Prep:: Quest Diagnostics Upgraded as Growth Outlook Brigh…